Akinwumni Ojo-Carons, MD
Urology · Suffolk, VANPI 1033378344
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 79.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $4,165 and has fallen 87.5% since, to $520 in 2025.
Across 145 payments — averaging $61.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Teleflex LLC$368
- Astellas Pharma US Inc$243
- Olympus America Inc.$175
- AbbVie$170
- Ferring Pharmaceuticals Inc.$138
- plus $759 from 18 others
Across 3 payments — averaging $4405.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$13K
What the payments were for
- Speaking & faculty fees$2,39027%
- Grants$1251%
- Travel & lodging$2,06423%
- Food & beverage$4,33248%
- Education$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 87 | $7,099 |
| Teleflex LLC | 6 | $368 |
| Astellas Pharma US Inc | 12 | $243 |
| Olympus America Inc. | 3 | $175 |
| AbbVie(2 entities) | 4 | $170 |
| Ferring Pharmaceuticals Inc. | 2 | $138 |
| Procept Biorobotics Corporation | 1 | $93 |
| Innovation Technologies Inc | 2 | $86 |
| Bayer | 4 | $75 |
| Coloplast | 5 | $62 |
| Progenics Pharmaceuticals, Inc. | 3 | $60 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $51 |
| Merck | 2 | $50 |
| Dornier Medtech America, Inc | 1 | $41 |
| Intuitive Surgical | 1 | $41 |
| Boston Scientific | 2 | $40 |
| Johnson & Johnson | 1 | $30 |
| Neotract Inc. | 2 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Coopersurgical, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$4,805
- URETERO-RENO VIDEOSCOPE$141
- UroLift$136
- NOCDURNA$125
- BOTOX$125
- UroLift System$114
How this compares
$8,951 in reported general payments places this provider in the 75th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 113 | $111,537 |
| GemtesaVibegron | 55 | $50,609 |
| Solifenacin Succinate | 73 | $3,709 |
| Tolterodine Tartrate ErTolterodine Tartrate | 51 | $3,362 |
| Trospium Chloride | 23 | $2,691 |
| Tamsulosin Hcl | 163 | $2,670 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,588 |
| Estradiol | 32 | $1,969 |
| Oxybutynin Chloride ErOxybutynin Chloride | 64 | $1,782 |
| Finasteride | 64 | $1,162 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $700 |
| Cefdinir | 59 | $531 |
| Cephalexin | 39 | $503 |
| CefuroximeCefuroxime Axetil | 35 | $440 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $243 | $111,537113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 300 urology providers in Virginia.
Other urology in Suffolk
- Patrick WhelanSuffolk$114K
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Jennifer Miles-ThomasVa Beach$101K
- Charles DanielRoanoke$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.